Alligator Bioscience

IPO

Tumor-directed immunotherapy of cancer

Sweden · Founded 2001 · $9.6M raised

Founded
2001
Business Model
B2B
Total Funding
$9.6M
Last Round
$9.6M Venture RoundDec 2025
Rounds
1

About

Alligator Bioscience is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, with a focus on the CD40 receptor pathway. By activating the patient's immune system inside the tumor microenvironment, its candidates aim to overcome immune suppression and drive anti-tumor responses. The lead asset, mitazalimab, is a CD40 agonist in preparation for Phase 3 after the Phase 2 OPTIMIZE-1 trial in first-line metastatic pancreatic cancer. The pipeline also includes mono- and bispecific antibody programs designed for localized immune activation. Founded in 2001, the company is listed on Nasdaq Stockholm under the ticker ATORX.

Summary

Alligator Bioscience is a Biotech company based in Sweden, founded in 2001. It has raised $9.6M in total across 1 round, most recently a $9.6M Venture Round round in Dec 2025.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Venture RoundRights IssueDec 2025
$9.6M

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Alligator Bioscience on Indexed.vc
<a href="https://indexed.vc/companies/alligator-bioscience"><img src="https://indexed.vc/api/badge/company/alligator-bioscience" alt="Alligator Bioscience on Indexed.vc" width="260" height="76" /></a>